Overview

Paxalisib (GDC-0084) In Recurrent Or Refractory PCNSL

Status:
Recruiting
Trial end date:
2024-05-01
Target enrollment:
Participant gender:
Summary
This research study is studying a drug called Paxalisib (GDC-0084) as a possible treatment for primary central nervous system lymphoma (PCNSL)
Phase:
Phase 2
Details
Lead Sponsor:
Lakshmi Nayak
Collaborator:
Kazia Therapeutics Limited
Treatments:
GDC-0084